Subscribe To
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 – – On track to report topline data from the Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN in the fourth quarter of 2023 – – Presented additional Phase 3 DeFi data at CTOS […] The post SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights appeared first on ForexTV...
Read More
Content Topics
Springworks
Therapeutics
Reports
Third
Quarter
2023
Financial
Results
Recent
Business
Highlights
Forex
Posted: Nov 2 2023, 10:30
Author Name: forextv
Views: 112273